Novo NordiskNVO
NVO
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
6% more call options, than puts
Call options by funds: $1.28B | Put options by funds: $1.21B
0.07% more ownership
Funds ownership: 9.87% [Q3] → 9.94% (+0.07%) [Q4]
8% less repeat investments, than reductions
Existing positions increased: 587 | Existing positions reduced: 638
8% less funds holding
Funds holding: 1,766 [Q3] → 1,631 (-135) [Q4]
24% less capital invested
Capital invested by funds: $39.6B [Q3] → $30.1B (-$9.51B) [Q4]
32% less first-time investments, than exits
New positions opened: 196 | Existing positions closed: 287
49% less funds holding in top 10
Funds holding in top 10: 61 [Q3] → 31 (-30) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NVO.
Financial journalist opinion
Based on 206 articles about NVO published over the past 30 days
Positive
CNBC International TV
19 hours ago
We see about 50% upside on Novo Nordisk, but there are risks, says strategist
Michael Field, chief EMEA equity strategist at Morningstar, discusses European stocks amid tariff uncertainty.
Positive
Zacks Investment Research
21 hours ago
Here's Why Novo Nordisk (NVO) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Negative
CNBC
21 hours ago
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Neutral
Investors Business Daily
1 day ago
Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.
Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.
Neutral
Zacks Investment Research
1 day ago
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
Positive
CNBC
2 days ago
Autos, pharma, luxury and more: The global sectors soaring after Trump's tariffs walkback
European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties on goods from China to 125% and citing a "lack of respect.
Neutral
CNBC Television
2 days ago
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Negative
Seeking Alpha
2 days ago
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading to drug shortages and higher domestic prices.
Negative
Reuters
2 days ago
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm to patients.
Negative
CNBC
2 days ago
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Charts implemented using Lightweight Charts™